Johan Cardoen joins GST’s board of directors
Press release: Global Stem cell Technology (GST) NV, a front-runner in the field of veterinary stem cell therapy, announces that Johan Cardoen joins the board of directors.
Evergem, Belgium – November 20, 2019
The main activities of GST are research and development and production of veterinary stem cell based products and their biotechnological applications. As a basis for stem cell therapies, GST uses highly potent stem cells from blood of mammals. GST thus translates regenerative medicine into clinical applications.
GST is a rapidly expanding veterinary biotech company and launched the first licensed stem cell product in veterinary medicine with Boehringer-Ingelheim this year1. The next product in the pipeline is designed to treat tendon injuries in horses and will be submitted for registration in 2020. Also the canine and feline pipeline is expanding rapidly with applications in osteoarthritis, stomatitis and kidney disease.
The pipeline is covered with 8 patents and based on more than 25 scientifically peer-reviewed publications in the field of veterinary regenerative medicine. GST is globally ranked within the top 10 start-ups in animal health2 and won the price for best start-up of the year by Animal Pharm in 20183. The vast growth of the company embodies the need for strategic decisions to be taken regularly. For this reason, an extension of the board of directors was indicated.
Jan Spaas, CEO at GST: “We are delighted to welcome Johan Cardoen as a board member of GST. He brings more than 30 years managerial experience working with R&D driven biotech companies and multinational life sciences companies on the one hand and establishing strategic partnerships on the other hand. He also shares the same values: being open, enthusiastic and passionate! We believe that he will add great value to the course GST is heading and look forward to collaborating with him on a regular basis. His willingness to join as a member of the board of directors confirms the strong position GST has obtained in the veterinary regenerative landscape.”
Griet Nuytinck, chairwomen of the board: “GST is part of Anacura since 5 years and we consider GST as the crown jewel in veterinary regenerative medicine. The company does not only possess a robust research and development department, but is also considered as a leader in production using our state-of-the-art clean room facilities and the personal and professional analytical support of Anacura.”
Johan Cardoen, board member GST: “I am proud to be part of this innovative and advanced company in veterinary regenerative medicine. Especially in veterinary medicine evidence-based and effective therapies are frequently lacking and GST plays a pivotal role in setting high standards. The company has proven to be successful in the development of a strong pipeline and in getting these products licensed by the highest authorities.”